**About the Editor**

#### **David R. Nalin**

David R. Nalin, MD, Dr.Sci.HC, Professor Emeritus, Center for Immunology and Microbial Diseases, Albany Medical College, Albany NY. After internship and medical residency (Montefiore, NYC) and senior residency (Harvard Service, BCH), Dr. Nalin attained the rank of Senior Surgeon In the U.S. Public Health Service, serving in Dhaka, Bangladesh (then E. Pakistan) as Research Associate, Office of International Research, NIH, and later Assistant Professor, medicine and pathobiology at Johns Hopkins Center for Medical Research and Associate Professor of medicine, international medicine and epidemiology and Director, U. Md. Pakistan Medical Research Center, Lahore. He is currently Professor Emeritus, Center for Immunology and Microbial Diseases, AMC.

Dr. Nalin led the team that first demonstrated that oral glucose-electrolyte solutions(ORS) reduced maintenance intravenous fluid needs by 80% in severe cholera, and published numerous studies demonstrating ORS effectiveness for most acute life-threatening watery diarrhoeal diseases for both rehydration and maintenance therapy. The BMJ estimated that by 1999 ORS saved over 70,000,000 lives.

As Director, Clinical Research, Vaccines and Infectious Diseases and Director, Vaccine Scientific Affairs at Merck (1983–2002) he designed and monitored studies of imipenem-cilastatin, norfloxacin and ivermectin, M-M-R® II, hepatitis A and HPV vaccines.

He has published over 100 peer-reviewed articles, over 200 letters, reviews, book chapters, and abstracts and holds three patents for new vaccination methods. His awards include the Pollin Prize for Pediatric Research and the Prince Mahidol Award 2006, recognizing his development of ORS; the AMC Humanitarian award (2010), the Friends of Liberation War Award Bangladesh (2013) and the Dr. Sci. H.C. degree from the University of Vermont (2017).
